Skip to content
← Back to this collection

PUBLICATIONS · 35930750

Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2022 Dec 22
First author
Handa S

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2022 Dec 22;140(25):2649-2650. doi: 10.1182/blood.2022017939.
    note
    Source null
    related pmid
    36548021
    relationship
    Comment in
  2. citation
    Blood. 2024 Nov 7;144(19):2068. doi: 10.1182/blood.2024026969.
    note
    Source null
    related pmid
    39509119
    relationship
    Erratum in

Authors and identifiers

  1. name
    Handa S
    type
    Author
  2. name
    Lee JO
    type
    Author
  3. name
    Derkach A
    type
    Author
  4. name
    Stone RM
    type
    Author
  5. name
    Saven A
    type
    Author
  6. name
    Altman JK
    type
    Author
  7. name
    Grever MR
    type
    Author
  8. name
    Rai KR
    type
    Author
  9. name
    Shukla M
    type
    Author
  10. name
    Vemuri S
    type
    Author
  11. name
    Montoya S
    type
    Author
  12. name
    Taylor J
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Handa S
    type
    Author
  2. name
    Lee JO
    type
    Author
  3. name
    Derkach A
    type
    Author
  4. name
    Stone RM
    type
    Author
  5. name
    Saven A
    type
    Author
  6. name
    Altman JK
    type
    Author
  7. name
    Grever MR
    type
    Author
  8. name
    Rai KR
    type
    Author
  9. name
    Shukla M
    type
    Author
  10. name
    Vemuri S
    type
    Author
  11. name
    Montoya S
    type
    Author
  12. name
    Taylor J
    type
    Author
bibliography ids
  1. nci-bib-5ac1ee6a0cf2c1b07af614ab
book metadata
content sha256
908b88626444db45118cfa80fcd811ae1dd2ade5b2196c10ec6bcdfa2a5ddfe1
document type
citation
dois
  1. 10.1182/blood.2022016183
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:35930750
immutable id
pubmed:35930750@908b88626444db45118cfa80fcd811ae1dd2ade5b2196c10ec6bcdfa2a5ddfe1
journal
abbreviation
Blood
issn electronic
1528-0020
issn print
0006-4971
issue
25
name
Blood
nlm unique id
7603509
pages
2663-2671
volume
140
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2022 Dec 22;140(25):2649-2650. doi: 10.1182/blood.2022017939.
    note
    Source null
    related pmid
    36548021
    relationship
    Comment in
  2. citation
    Blood. 2024 Nov 7;144(19):2068. doi: 10.1182/blood.2024026969.
    note
    Source null
    related pmid
    39509119
    relationship
    Erratum in
outcomes validated
false
pmid
35930750
provenance
batch id
9d150d55960e0c12aada
provider
NCBI PubMed ESummary
record sha256
5ebf4b2a3c760099eb393c05586424b5b8bdce4450c0da7e6f3b6598daf5b21d
response sha256
2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
retrieved at
2026-09-09T23:48:09.820498+00:00
publication date
display
2022 Dec 22
precision
day
year
2022
publication types
  1. Journal Article
  2. Research Support, N.I.H., Extramural
  3. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35930750/
title
Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy.

Preserved source evidence · Not medical advice